Skip to content

Legend Biotech

US · LEGN #2374 by market cap Listed 2020
15.25 -0.85 -5.28%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 10 in the most recent period (2026/Q3).
  • Total institutional ownership fell 3.9 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
103.67% -3.87pp
Institutions
271 -10
As of
2026/Q3 vs. prior period

Holder types

Public Company47.96%
Mutual Fund27.67%
Hedge Fund15.90%
Private Company8.28%
VC/PE Fund3.51%
Government Pension Fund0.21%
Individual/Insider0.12%
Insurance Company0.10%
Other46.99%

Top holders as of 2026-02-15

Genscript Biotech Corporation 44.98% · 87.25M sh
FMR 12.32% · 23.91M sh
AquaPoint L.P. 7.80% · 15.14M sh
Deerfield Management Company, L.P. 4.20% · 8.14M sh
Montanova Capital, LLC 3.64% · 7.07M sh
Hillhouse Capital Management, Ltd. 3.09% · 5.98M sh
BlackRock 2.63% · 5.09M sh
Westfield Capital Management Company, L.P. 2.28% · 4.43M sh
Kynam Capital Management, LP 1.55% · 3.00M sh
The Goldman Sachs Group, Inc. 1.87% · 3.63M sh
Point72 Asset Management, L.P. 1.59% · 3.08M sh
Assenagon Asset Management S.A. 0.99% · 1.92M sh
Artisan Partners Limited Partnership 0.80% · 1.56M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

49 filings tracked · 0 buys · 41 sells

NameRoleStake
Ying Huang Former Chief Executive Officer 0.06%
Xiaohui Ji Independent Director 0.01%
Patrick Casey Independent Director 0.01%
Li Mao Independent Director 0.01%
Tomas Heyman Independent Director 0.01%
Corazon Sanders Independent Director 0.01%
Gareth Kung Independent Director --
Jessie Yeung Former Vice President of Finance, Investor & Public Relations --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-03-25 Ying Huang Former Chief Executive Officer Intent to Sell (Form 144) -4,968 $17.54
2026-03-25 Jessie Yeung Former Vice President of Finance, Investor & Public Relations Intent to Sell (Form 144) -1,862 $17.54
2026-03-17 Corazon Sanders Independent Director Initial Statement of Beneficial 0 --
2026-03-17 Ying Huang Former Chief Executive Officer Initial Statement of Beneficial 0 --
2026-03-17 Gareth Kung Independent Director Initial Statement of Beneficial 0 --
2026-03-17 Xiaohui Ji Independent Director Initial Statement of Beneficial 0 --
2026-03-17 Tomas Heyman Independent Director Initial Statement of Beneficial 0 --
2026-03-17 Patrick Casey Independent Director Initial Statement of Beneficial 0 --
2026-03-17 Li Mao Independent Director Initial Statement of Beneficial 0 --
2025-12-25 Ying Huang Former Chief Executive Officer Intent to Sell (Form 144) -64,339 $22.52
2025-12-23 Corazon Sanders Independent Director Intent to Sell (Form 144) -969 $22.77
2025-12-23 Ying Huang Former Chief Executive Officer Intent to Sell (Form 144) -61,467 $22.95
2025-11-16 GenScript Corporation -- Intent to Sell (Form 144) -203,586 $30.29
2025-09-25 Patrick Casey Independent Director Intent to Sell (Form 144) -1,000 $33.29
2025-09-23 Ying Huang Former Chief Executive Officer Intent to Sell (Form 144) -1,370 $33.00
2025-09-22 Corazon Sanders Independent Director Intent to Sell (Form 144) -307 $34.00
2025-09-22 Ying Huang Former Chief Executive Officer Intent to Sell (Form 144) -1,357 $33.98
2025-09-22 Jessie Yeung Former Vice President of Finance, Investor & Public Relations Intent to Sell (Form 144) -474 $33.98
2025-07-22 Ying Huang Former Chief Executive Officer Intent to Sell (Form 144) -15,291 $45.04
2025-06-25 Patrick Casey Independent Director Intent to Sell (Form 144) -1,000 $33.23

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.

Legend Biotech discussion 0 comments

Add a comment